Court Blocks Rule on Mailing Abortion Drug Mifepristone

A U.S. appeals court temporarily blocked a federal rule allowing the abortion drug mifepristone to be mailed, impacting national access. This stems from a challenge by Louisiana against a 2023 rule from the Biden administration, highlighting ongoing legal battles over abortion rights and medication access in Republican-led states.

In a significant legal development, a U.S. appeals court on Friday halted a federal rule permitting the mailing of the abortion drug mifepristone, thereby restricting access to the medication across the country. The New Orleans-based 5th U.S. Circuit Court of Appeals made this decision in response to a lawsuit filed by the state of Louisiana.

This ruling is part of a broader legal struggle over abortion rights in the United States, with nearly half of the states imposing bans or severe restrictions following the U.S. Supreme Court's rollback of abortion rights in 2022. The legal battles have intensified the focus on medication abortion, which now accounts for a significant percentage of abortion procedures.

The Biden administration and drug manufacturers are defending the safety and efficiency of mifepristone, arguing against Louisiana's claims. Meanwhile, lawsuits from Republican-led states challenge the FDA's handling of the drug's regulations. As legal proceedings continue, access to mifepristone remains a contentious issue.